Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765310 · ClinicalTrials.gov registry record · Phase 1
Lipoic Acid and Prevention of Heart Disease
A Phase 1 study, sponsored by Oregon State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT00765310: Completed Phase 1 study, sponsored by Oregon State University.
NCT00765310 is a Phase 1 study that has completed, run by Oregon State University. The registered enrollment target is 81 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00765310, a Phase 1 study, has completed, sponsored by Oregon State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to reduce risk factors such as body weight and high blood cholesterol levels in overweight or obese participants.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT R-alpha lipoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2009-04-01 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 1 |
What the finished NCT00765310 record still lists
NCT00765310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00765310 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00765310 about?
NCT00765310 is a clinical study titled "Lipoic Acid and Prevention of Heart Disease". The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to reduce risk factors such as body weight and high blood cholesterol levels in overweight or obese participants.
What is the current status of trial NCT00765310?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2009-04-01. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT00765310?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), R-alpha lipoic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00765310?
This trial is sponsored by Oregon State University, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00765310's enrollment target sits among peer trials
81 671st of 2000 higher than 1,329 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI